Clinical Trials · NCT03419624
The Potential of Dapagliflozin Plus Exenatide in Obese Insulin-resistant Patients
- Phase
- Phase 3
- Recruitment status
- Terminated
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
- Enrollment
- 13
- Start date
- Feb 2018
- Locations
- 4 sites, Germany
- Primary endpoint
- Change in HbA1c from baseline (week 0) to week 28